Imlunestrant (Inluriyo) for Advanced Breast Cancer
Abstract
The FDA has approved imlunestrant (Inluriyo – Lilly), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in adults who had disease progression following at least one prior line of endocrine therapy. Imlunestrant is the second oral selective estrogen receptor degrader (SERD) to be approved in the US for treatment of breast cancer; elacestrant (Orserdu) was approved in 2023.
Fields of Study & Subjects
Advanced Breast Cancer Therapies
Estrogen and related hormone effects
HER2/EGFR in Cancer Research
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1746
- Pages
- 14–15
- Publication date
- 19 January 2026
- Language
- EN